Christina Messiou1, David Collins1,
Veronica Morgan1, Sharon Giles1, Catherine Parry-Jones1,
Faith Davies2, Gareth Morgan3, Nandita deSouza1
1CRUK and EPSRC Cancer Imaging Centre,
Department of Magnetic Resonace Imaging, Institute of Cancer Research/The
Royal Marsden Hospital, Sutton, Surrey, United Kingdom; 2Molecular
Target Treatment Team, Institute of Cancer Research/The Royal Marsden
Hospital, Sutton, Surrey, United Kingdom; 3Leukaemia and Molecular
Genetics Team, Institute of Cancer Research/The Royal Marsden Hospital,
Sutton, Surrey, United Kingdom
There
is growing interest in diffusion weighted (DW) MRI as a biomarker of
treatment response in metastatic and myeloma bone disease. We performed an
ROC analysis of normal vs myeloma involved marrow. Using an ADC threshold of
724 mm2s-1 x 10-6 the sensitivity and specificity for detecting myeloma
marrow involvement are 90 and 70% respectively. This threshold was applied to
a test case to produce segmented ADC maps which were used to predict
treatment response.